HAB HIV Performance Measures: 

ADAP: AIDS Drug Assistance Program 

Performance Measure: ADAP: Application Determination 

Percent of ADAP applications1 approved or denied for new ADAP enrollment2 within 14 days (two weeks) 

of ADAP receiving a complete application in the measurement year 

Numerator: 

Number of applications that were approved or denied for new ADAP enrollment1 within 

14 days (two weeks) of ADAP receiving a complete application in the measurement 

year 

Denominator: Total number of complete ADAP applications for new ADAP enrollment2

 received in 

the measurement year 

Exclusions: 

1. ADAP applications for new ADAP enrollment2 that were incomplete or incorrectly 

filled out. 

2. Complete ADAP applications for new ADAP enrollment2

 received by ADAP within 

the last 14 days (two weeks) of the measurement year. 

Data Element: 

1. Did the client apply for new ADAP enrollment2 during the measurement year? 

(Y/N) 

a. If yes, was a determination on the application made by the ADAP program? 

(Y/N) 

i. If yes, list the date of receipt of the complete application and date of 

approval or denial. 

Data Sources:  AIDS Drug Assistance Program Quarterly Data Report 

National Goals, 

Targets, or 

Benchmarks for 

Comparison: 

Part B Collaborative3: 97% 

Part B Low Incidence Initiative4: 100% 

Basis for Selection: 

Timely review for ADAP eligibility can ensure timely access to medications. This quality measure has been 

used by the Part B Collaborative and Low Incidence Initiative to measure performance and to develop 

successful improvement projects to decrease the length of time to determine ADAP eligibility or ineligibility 

by the ADAP program. 

US Public Health Service Guidelines: 

This measure addresses the intent of HHS Treatment Guidelines for the use of antiretroviral agents and the 

prevention and treatment of opportunistic infections in HIV-infected individuals.5 - 9 

References/Notes: 

1 Includes applications for all individuals, regardless of age. 

2

New ADAP enrollment “refers to individuals who applied to ADAP for the first time ever.... [This does not] include 

individuals who have been recertified as eligible or individuals who have been reinstated as enrolled clients after a 

ADAP Final |December 10, 2009 | Page 1 of 9 
 

HAB HIV Performance Measures: 

ADAP: AIDS Drug Assistance Program 

Performance Measure: ADAP: Application Determination 

period of having been decertified. Examples of clients who should not be included [as a new ADAP enrollment] are 

the following: 1) clients who have moved out of the State and then returned; and 2) clients who move on and off 

ADAP because of fluctuations in eligibility for a Medicaid/Medically Needy program, based on whether they met 

spend down requirements.” 

[Source: “Instructions for Completing The Drug Assistance Program Quarterly Data Report”. Available at 

ftp://ftp.hrsa.gov/hab/ADAP%20Instructions_Final%20_Feb%2022_08_.pdf. Accessed July 17, 2009.] 

3

 Part B Collaborative measure reads: “Percent of ADAP applicants approved or denied for ADAP enrollment within 

two weeks of ADAP receiving a complete application”. 

4

 Part B Low Incidence Initiative measure reads: “Percent of applying state ADAP clients approved/denied for ADAP 

services within two weeks of ADAP receiving a complete application”. 

5 Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral 

agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1, 

2009; 1-161.. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 

December 7, 2009. 

6 Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the 

Use of Antiretroviral Agents in Pediatric HIV Infection. February 23, 2009; pp 47. Available at 

http://aidsinfo.nih.gov/ContentFiles/PediatricGuidelines.pdf. Accessed September 9, 2009. 

7 Perinatal HIV Guidelines Working Group. Public Health Service Task Force Recommendations for Use of 

Antiretroviral Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce 

Perinatal HIV Transmission in the United States. April 29, 2009; pp 1-90. Available at 

http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf. Accessed September 9, 2009. 

8 Centers for Disease Control and Prevention. Guidelines for Prevention and Treatment of Opportunistic Infections in 

HIV-Infected Adults and Adolescents. MMWR 2009;58(No. RR-4): 1-216. Available at: 

http://www.cdc.gov/mmwr/pdf/rr/rr5804.pdf. Accessed September 9, 2009. 

9 Centers for Disease Control and Prevention. Guidelines for the Prevention and Treatment of Opportunistic Infections 

Among HIV-Exposed and HIV-Infected Children. MMWR 2009;58(No. RR-11): 1-176. Available at: 

http://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf. Accessed September 9, 2009. 

ADAP Final |December 10, 2009 | Page 2 of 9